Vaxxinity is a biotechnology company. Co.'s pipeline consists of five chronic disease product candidates including UB-311, which targets toxic forms of aggregated Ab in the brain to fight Alzheimer's Disease; UB-312, which targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's Disease and other synucleinopathies; an anti-tau product candidate that has the potential to address various neurodegenerative conditions; UB-313, which targets Calcitonin Gene-Related Peptide to fight migraines; and Anti-PCSK9, which targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events. We show 1 historical shares outstanding datapoints in our coverage of VAXX's shares outstanding history.
Understanding the changing numbers of VAXX shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like VAXX versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching VAXX by allowing them to research VAXX shares outstanding history
as well as any other stock in our coverage universe. |
Free VAXX Email Alerts:
Video: Shares Outstanding Importance
